# US 2022/0031872 A1 · Lyophilized Compositions Comprising Rhannexin V-128, Process for Their Preparation and Their Use for Preparing Formulations Containing 99MTc-Rhannexin V-128

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031872 A1
- Document ID: US20220031872A1
- Status: Published application
- Kind: A1
- Application number: 17/398,195
- Filed: 2021-08-10
- Published: 2022-02-03
- Earliest claimed: 2016-10-11
- Assignees: Advanced Accelerator Applications International SA
- Applicants: Advanced Accelerator Applications International S.A.
- Inventors: Lorenza Fugazza; Maurizio Franco Mariani; Francesca Orlandi; Daniela Chicco; Donato Barbato
- Web page: https://patentgrep.com/patent/US20220031872A1

## CPC

- A61K 51/087: {the peptide being an annexin, e.g. annexin V}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1611: {Inorganic compounds}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 38/1709: {from mammals}
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

It is described a composition comprising lyophilized rhAnnexin V-128 suitable for the preparation of 99mTc-rhAnnexin V-128 formulations suitable for intravenous administration.

## Claims

### Claim 1

A lyophilized composition suitable for intravenous administration comprising rhAnnexin V-128 in combination with an antioxidant agent, in a pH range of 5.0-6.6.

### Claim 2 (depends on 1)

The lyophilized composition according to claim 1 wherein the antioxidant agent is chosen among: sodium metabisulfite, nicotinamide, pyridoxine hydrochloride, a-tocopherol acetate, monothioglycerol.

### Claim 3 (depends on 1)

The lyophilized composition according to claim 1, comprising also a buffer, chosen among lactate buffer, succinate buffer, glycolic buffer, TRIS, histidine buffer.

### Claim 4 (depends on 1)

A lyophilized composition according to claim 1, suitable for intravenous administration, comprising:
an antioxidant agent,
a buffer having a pH comprised between 5.0-6.6;
a reducing agent;
a transchelating agent;
a lyoprotectant and cake-forming agent;
and possibly a radiation stability enhancer and/or a solubilizer.

### Claim 5 (depends on 4)

The lyophilized composition according to claim 4 wherein said components are present in the following quantities:
the antioxidant agent in a quantity above 0.005 mg/vial
the buffer having a pH comprised between 5.0-6.6 with a concentration above 10 mM;
the reducing agent, in a quantity above 0.005 mg/vial;
the transchelating agent, in a quantity above 0.02 mg/vial;
the lyoprotectant and cake-forming agent, in a quantity above 10 mg/vial the radiation stability enhancer and the solubilizer, if present, in a quantity above 0.005 mg/vial and above 1 mg/vial respectively.

### Claim 6 (depends on 1)

A process for preparing a lyophilized formulation according to claim 1 comprising the following steps:
thawing of the frozen rhAnnexin V-128;
adding an antioxidant/reducing agent,
buffer exchange by tangential flow filtration, to substitute the buffer in which the rhAnnexin V-128 is supplied with a buffer chosen among lactate buffer, succinate buffer, glycolic buffer, TRIS, and histidine buffer;
preparation of the excipient bulk solution including: transchelating agent, radiation stability enhancer, solubilizer, antioxidant agent, lyoprotectant and cake-forming agent;
addition of the required volume of rhAnnexin V-128 solution to the excipient bulk solution;
dispensation of the bulk solution into vials and lyophilization.

### Claim 7 (depends on 1)

A formulation suitable for intravenous administration comprising a 99mTc-rhAnnexin V-128 obtained by reacting a single-vial lyophilized rhAnnexin V-128 formulation according to claim 1 with an eluate from a commercial 99mTc04-generator.

### Claim 8 (depends on 7)

A process for obtaining a 99mTc-rhAnnexin V-128 according to claim 7 comprising the following steps:
adding a suitable volume of eluate from a commercial 99mTc04-generator containing up to 740 MBq of radioactivity to the vial containing the lyophilized formulation; and
rotating the vial for 90 minutes at room temperature.

### Claim at position 9

9-13. (canceled)

### Claim 14 (depends on 7)

A method for monitoring treatment efficacy of a disease in a subject, comprising the administration of the formulation according to claim 7 to the subject, wherein the disease is selected in the group consisting of rheumatic diseases, cardiovascular diseases, oncology, transplant rejection, autoimmune diseases, neurologic diseases and atherosclerosis.

### Claim 15 (depends on 7)

A method of diagnosing a disease in a subject comprising the administration of the formulation according to claim 7, wherein said disease is selected in the group consisting of rheumatic diseases, cardiovascular diseases, oncology, transplant rejection, autoimmune diseases, neurologic diseases and atherosclerosis.

### Claim 16 (depends on 15)

The method according to claim 15, wherein said cardiovascular diseases are selected from the group consisting of aortic aneurysm, chemotherapy cardiotoxicity, endocarditis and myocarditis.

### Claim 17 (depends on 15)

The diagnostic method according to claim 15, wherein said rheumatic diseases are selected from the group consisting of rheumatoid arthritis and Axial Spondyloarthritis.

### Claim 18 (depends on 15)

The diagnostic method according to claim 15, wherein said disease is atherosclerosis, and said diagnostic method detects and stages atherosclerotic plaque.

### Claim 19 (depends on 14)

The method of claim 14, wherein the subject is a human subject.

### Claim 20 (depends on 15)

The method of claim 15, wherein the subject is a human subject.
